Abzu Analysis: $11M Raised
What is Abzu?
Abzu specializes in AI-powered drug design, focusing on RNA therapeutics. Their unique approach combines explainable AI with data-driven methodologies to enhance drug discovery. This results in higher success rates and faster development timelines for pharmaceutical research and development.
Employees
11-50
Founded
2018
Industry
AI/ML, Biotech, HealthTech
Product Features & Capabilities
- AI-guided drug design process for RNA therapeutics
- Predictive models for drug properties like activity and cross-reactivity
- Ready-to-use compound designs with detailed selection reports
- One-stop solution for design and in-vitro validation
- Integration of existing data into predictive models.
Use Cases
Maximize success by testing only the best compounds; Reduce design time and project management overhead; Generate predictive models for siRNA activity; Design active and safe ASOs; Validate candidates through in-vitro screening.
How much Abzu raised
Grant (prize money) - $2.43M
Oct 15, 2022Lead Investor: EIC Fund
Seed - $6.87M
Feb 26, 2021Lead Investor: Seed Capital, Inventure, and 2 more
Seed - $63.6K
Sep 04, 2020Lead Investor: None listed
Seed - $1.92M
Jul 05, 2019Lead Investor: Nordic Ventures, Inventure, and 1 more
Seed - $178K
Jan 25, 2018Lead Investor: PSV Deeptech
See something that needs updating? Suggest edits to this profile.
Financial Overview
$11MTotal Raised
Grant (prize money)$2.43M
Oct 15, 2022
Investors: EIC Fund
Seed$6.87M
Feb 26, 2021
Investors: Seed Capital, Inventure, and 2 more
Seed$63.6K
Sep 04, 2020
Investors: None listed
Seed$1.92M
Jul 05, 2019
Investors: Nordic Ventures, Inventure, and 1 more
Seed$178K
Jan 25, 2018
Investors: PSV Deeptech
